eScholarship@UMMS

Title

Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer

Authors

Byoung H. Kang, University of Massachusetts Medical SchoolFollow
Markus D. Siegelin, University of Massachusetts Medical SchoolFollow
Janet Plescia, University of Massachusetts Medical SchoolFollow
Christopher M. Raskett, University of Massachusetts Medical SchoolFollow
David S. Garlick, University of Massachusetts Medical SchoolFollow
Takehiko Dohi, University of Massachusetts Medical SchoolFollow
Jane B. Lian, University of Massachusetts Medical SchoolFollow
Gary S. Stein, University of Massachusetts Medical SchoolFollow
Lucia R. Languino, University of Massachusetts Medical SchoolFollow
Dario C. Altieri, University of Massachusetts Medical SchoolFollow

UMMS Affiliation

Department of Cell Biology; Department of Cancer Biology

Publication Date

2010-09-30

Document Type

Article

Subjects

Prostatic Neoplasms; HSP90 Heat-Shock Proteins; Mitochondria

Disciplines

Cell Biology

Abstract

PURPOSE: This study aimed to characterize the preclinical activity of the first class of combinatorial, mitochondria-targeted, small molecule heat shock protein-90 (Hsp90) inhibitors, gamitrinibs, in models of hormone-refractory, drug-resistant, localized, and bone metastatic prostate cancer in vivo.

EXPERIMENTAL DESIGN: Mitochondrial permeability transition, apoptosis, and changes in metabolic activity were examined by time-lapse videomicroscopy, multiparametric flow cytometry, MTT, and analysis of isolated mitochondria. Drug-resistant prostate cancer cells were generated by chronic exposure of hormone-refractory PC3 cells to the Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG). The effect of gamitrinibs on s.c. or intratibial prostate cancer growth was studied in xenograft models. Bone metastatic tumor growth and bone parameters were quantified by micro-computed tomography imaging.

RESULTS: In the NCI 60-cell line screening, gamitrinibs were active against all tumor cell types tested, and efficiently killed metastatic, hormone-refractory, and multidrug-resistant prostate cancer cells characterized by overexpression of the ATP binding cassette transporter P-glycoprotein. Mechanistically, gamitrinibs, but not 17-AAG, induced acute mitochondrial dysfunction in prostate cancer cells with loss of organelle membrane potential, release of cytochrome c, and caspase activity, independently of proapoptotic Bcl-2 proteins Bax and Bak. Systemic administration of gamitrinibs to mice was well tolerated, and inhibited s.c. or bone metastatic prostate cancer growth in vivo.

CONCLUSIONS: Gamitrinibs have preclinical activity and favorable safety in models of drug-resistant and bone metastatic prostate cancer in vivo.

DOI of Published Version

10.1158/1078-0432.CCR-10-1818

Source

Clin Cancer Res. 2010 Oct 1;16(19):4779-88. Epub 2010 Sep 28. Link to article on publisher's site

Journal/Book/Conference Title

Clinical cancer research : an official journal of the American Association for Cancer Research

Related Resources

Link to Article in PubMed

PubMed ID

20876793

Repository Citation

Kang, Byoung H.; Siegelin, Markus D.; Plescia, Janet; Raskett, Christopher M.; Garlick, David S.; Dohi, Takehiko; Lian, Jane B.; Stein, Gary S.; Languino, Lucia R.; and Altieri, Dario C., "Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer" (2010). Stein, Stein, Lian, vanWijnen Lab Publications. 5.
https://escholarship.umassmed.edu/stein/5